Puff Puff Post

MARCH 2, 2020

. · Domestic quotas represent a further milestone in the Company’s stated timeline to bring the first medical cannabis products to market in Colombia, targeting patients with two priority conditions; chronic pain and nausea associated with chemotherapy. United States Disclaimer. Securities Act) unless registered under the U.S.

Extraction 40

Extraction THC Chronic Pain Cultivation 40

MMJ Recs

MARCH 2, 2024

A: Qualifying medical conditions in Ohio include cancer, PTSD, chronic pain, epilepsy, and more. Understanding Ohio’s Medical Marijuana Laws Understanding Ohio’s Medical Marijuana Laws is crucial for patients, caregivers, and dispensary operators participating in the state’s program.

Dispensary 52

Dispensary Patients Marijuana Education 52

SpeedWeed

MAY 5, 2021

Last week was eventful for cannabis reform in Texas, as the House of Representatives approved three legislative proposals, which would expand the state’s medical cannabis program, reduce penalties for concentrates and decriminalize possession.

Programs 52

Programs Chronic Pain Concentrates THC 52

SpeedWeed

MAY 4, 2021

Last week was eventful for cannabis reform in Texas, as the House of Representatives approved three legislative proposals, which would expand the state’s medical cannabis program, reduce penalties for concentrates and decriminalize possession.

Programs 52

Programs Chronic Pain Concentrates THC 52

Cannabis Law Report

OCTOBER 19, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

AUGUST 24, 2021

The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to treat aging and longevity, autoimmune diseases, and COVID-19- associated depression and cytokine elevation. Investor Contact: Robert Schatz. 646) 421-9523.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

DECEMBER 1, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

MMJ Recs

OCTOBER 2, 2023

Today we’re here to explore the best medical marijuana dispensaries in California, as well as provide guidance on how to obtain a medical marijuana card, relevant state laws, the difference between recreational and medical marijuana, regulations governing medical cannabis, qualifying conditions, and the role of medical marijuana doctors.

Dispensary 52

Dispensary Patients Environment Conditions 52

Cannabis Law Report

OCTOBER 5, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. Investor: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

SEPTEMBER 22, 2021

Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Otherside Farms

JANUARY 17, 2020

The Food and Drug Administration allows the use of CBD to treat pain, anxiety, depression, nausea, and some types of epilepsy. CBD can quell pain; it is not easy to have a good appetite when you are in pain. It is so uncomfortable and disturbing when one is in pain. Cannabis brings fun at social events.

Food 52

Food Research and Development Seed-To-Sale Vaping 52

Cannabis Law Report

MAY 6, 2022

Generally, a CBD product seller is expected (or required by law) to provide customers with access to a “certificate of analysis” or “COA” associated with specific products, which COA confirms the levels of CBD in products and upon which customers can rely. Taking CBD can relieve pain.”.

THC 52

THC CBD Media Food 52

Cannabis Law Report

NOVEMBER 23, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. MyMD Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

SEPTEMBER 13, 2021

The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to treat aging and longevity, autoimmune diseases, and COVID-19- associated depression and cytokine elevation. 3 Nature Aging | VOL 1 | July 2021 | p. 616–623.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JANUARY 5, 2022

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. 2 Goates et al. 3 Koon Yee-Lee et al. 4 [link].

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 16, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. MyMD Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 26, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. 1 Data published by Research and Markets, March 2018. MyMD: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

FEBRUARY 18, 2020

This guide will uncover key facts about recreational and medical marijuana use and the history of its laws in the state of New York. . Over the next 50 years, several studies surrounding marijuana use and its effects were conducted as the state introduced new laws. History of Marijuana Legislation in New York.

Marijuana 59

Marijuana Consumption Dispensary Vaping 59

Cannabis Law Report

SEPTEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, has acquired the exclusive worldwide rights from Nanomerics Ltd. Christopher M. Chipman, CPA. Chief Financial Officer. cchipman@virpaxpharma.com 610-727-4597. Betsy Brod.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 10, 2021

The NIH has also engaged a firm to manufacture Leu-enkephalin (L-ENK), the active ingredient in Envelta and a firm to manufacture the Molecular Envelope Technology (MET) that is used to carry the L-ENK to the brain to promptly suppress pain. In October 2021, Virpax announced that a $1.87 Forward-Looking Statement. Christopher M. Chipman, CPA.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

DECEMBER 20, 2021

About Epoladerm™ Virpax Pharmaceuticals is developing Epoladerm™ (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film to manage chronic pain associated with osteoarthritis of the knee. For more information, please visit www.virpaxpharma.com.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

SEPTEMBER 23, 2019

During the 20 th century, law enforcement and public policy activities have undermined opportunities for scientific exploration. The AAFP also recognizes that several states have passed laws approving limited recreational use and/or possession of marijuana. Cannabinoids have been assessed for chronic pain management.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Cannabis Law Report

JANUARY 4, 2022

(“Virpax”), a company specializing in product candidates for pain management, CNS disorders and anti-viral indications, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, January 10 th through Thursday, January 13 th starting at 7:00 a.m. Event: Virpax Pharma Presentation at the H.C.

Pharmaceutical 52

Pharmaceutical Research and Development Chronic Pain Events 52

Cannabis Law Report

AUGUST 2, 2021

Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

OCTOBER 6, 2021

Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children, a rare pediatric disease.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

NOVEMBER 15, 2021

Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer. for its MET for the nasal delivery of cannabidiol (CBD) for the management of epilepsy in children (rare pediatric disease) and adults.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 1, 2021

Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. About Noble Capital Markets, Inc.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

Cannabis Law Report

DECEMBER 8, 2021

About Epoladerm™ Virpax Pharmaceuticals is developing Epoladerm™ (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film to manage chronic pain associated with osteoarthritis of the knee. For more information, please visit www.virpaxpharma.com.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

DECEMBER 28, 2021

We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Envelta™ Envelta is an endogenous enkephalin intranasal spray for acute and chronic pain, including pain associated with cancer. Forward-Looking Statement.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 24, 2021

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Before 2016, Australian law considered cannabis an illegal drug. Refractory paediatric epilepsy. Cancer pain. Conclusions.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

MARCH 6, 2020

The Company’s KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. This is the sixth patent grant that Kannalife has received. to be materially different from the statements made herein.

Research and Development 59

Research and Development Marijuana Pharmaceutical Supply Chain 59

Cannabis Law Report

NOVEMBER 18, 2021

Nadav Kidron, Oramed CEO and Oravax Chairman, and Rodrigo Herrera, Genomma Lab Chairman, will hold a joint press event today, Thursday, November 18, 2021 at 11:00 am EST. The live press event will be available via Zoom. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

DECEMBER 29, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Cannabis Law Report

OCTOBER 11, 2021

The previous law allowed only those with terminal cancer to use low-THC medical marijuana. A Texas medical marijuana clinic in Houston provides an example of how the law change might help PTSD patients. PTSD patients include both those who experienced a traumatic event and those who have witnessed such an event.

Patients 52

Patients Marijuana Chronic Pain Programs 52

The Cannigma

OCTOBER 8, 2021

The laws on cannabis are covered in the country’s Misuse of Drugs Act of 1971 which lists a litany of regulations covering cannabis and other drugs. The law states that it is also illegal for occupiers of premises to permit certain activities like smoking cannabis. What British law permits for medical patients.

Legalization 52

Legalization Medicine Conditions Patients 52

Cannabis Law Report

OCTOBER 17, 2019

Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma. how the segments are defined (e.g.,

Law 40

Law Seed-To-Sale Hemp Recreational 40

Cannabis Law Report

DECEMBER 30, 2019

Over 60 cannabis-related bills were signed into law in states across the country. 2019 has been an unprecedented year for the passage of state-level marijuana law reforms. The law took effect immediately upon the Governor’s signature on June 5, 2019. ” Director’s Statement. State Legislative Victories.

Legislation 59

Legislation Patients Access Banking 59